Trial Profile

Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized Approach

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Botulinum-Toxin-A (Primary)
Indications Parkinson's disease; Tremor
Focus Therapeutic Use

Most Recent Events

05 Aug 2017 Results (n=30) published in the Mayo Clinic Proceedings
21 Apr 2016 Primary endpoint of Unified Parkinsons Disease Rating Scale (UPDRS) Tremor Scale has been met, according to results published in the 68th Annual Meeting of the American Academy of Neurology.
21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com